DENVER, Dec. 10 /PRNewswire-FirstCall/ -- Global Med Technologies(R), Inc. ("Global Med" or the "Company") (OTC:GLOB) (BULLETIN BOARD: GLOB) , an international e-Health, medical information technology company, today announced that due to inquiries from stockholders, Global Med is clarifying that the letter that was received from Victory Park Capital Advisors, LLC ("VPC") on December 9, 2008 was a proposal to Global Med's Board of Directors to investigate various business opportunities for the Company. VPC's letter does not constitute an offer to Global Med's shareholders to acquire the outstanding securities of Global Med not already held by VPC. (Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO) About Global Med Technologies(R), Inc. Global Med Technologies, Inc. is an international medical software company which develops regulated and non-regulated software products and services for the healthcare industry. As a leading provider of blood and laboratory software applications and services, Global Med's products are deployed in 20 countries and serve over 1,600 transfusion centers, blood banks and laboratories. Global Med's domestic companies are Wyndgate Technologies(R), which provides Vein-to-Vein(R) tracking through its Donor Doc(TM), SafeTrace(R), SafeTrace Tx(R) and ElDorado Donor(TM) software products; eDonor(R), which provides a web-based donor relationship management system that integrates recruitment, scheduling, retention and fulfillment for national as well as local community blood centers and hospitals; and PeopleMed(TM), Inc., which implements cost-effective customized software validation, consulting and compliance solutions to hospitals and donor centers. Global Med's European subsidiary, Inlog, SA, is a leading developer of donor center and transfusion management systems as well as cellular therapy software, laboratory information systems and quality assurance medical software systems internationally. Inlog's products include EdgeBlood*, EdgeTrack*, EdgeCell, EdgeLab and SapaNet. For more information about Global Med's products and services, please call 800-996-3428 or visit http://www.globalmedtech.com/, http://www.peoplemed.com/, http://www.inlog.com/, http://www.edonor.com/, and http://www.wyndgate.com/. *FDA 510(k) clearance required prior to sales in the U.S. This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release. http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies, Inc. CONTACT: Michael I. Ruxin, M.D., of Global Med Technologies, Inc., +1-303-238-2000, ; or Investors, Paul Holm, President of portfolio pr, +1-212-888-4570, , for Global Med Technologies, Inc. Web site: http://www.globalmedtech.com/

Copyright